Additional Information

Description

Flucelvax® 2025–2026 (Flu-109) is a cell-based, inactivated quadrivalent influenza vaccine designed for immunization against the influenza A and B virus strains projected for the 2025–2026 season. Produced using Madin-Darby Canine Kidney (MDCK) cells, this vaccine avoids egg-adapted mutations, potentially improving antigenic match and immune response. It contains purified hemagglutinin antigens from two A strains and two B strains as per annual recommendations.

The product is supplied in 0.5 mL prefilled syringes, packaged with 10 single-dose units per box. It is indicated for individuals aged 6 months and older. Each 0.5 mL dose is administered intramuscularly, typically into the deltoid muscle for adults or the anterolateral thigh for infants and young children. The formulation is preservative-free, reducing the risk of adverse reactions related to additives and ensuring ease of administration in clinical settings.

Reported side effects include pain at the injection site, headache, fatigue, myalgia, and redness. Infrequent but serious adverse events such as hypersensitivity reactions and Guillain-Barré syndrome have been documented. The vaccine is contraindicated in individuals with severe allergic reactions to any component of the formulation or prior doses.